Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Abstract Background Adjuvant bisphosphonates are associated with improved breast cancer survival in postmenopausal patients. Addition of zoledronic acid (ZA) to neoadjuvant chemotherapy did not improve pathological complete response in the phase III NEOZOTAC trial. Here we report the results of the...

Full description

Bibliographic Details
Main Authors: Stefanie de Groot, Hanno Pijl, Ayoub Charehbili, Saskia van de Ven, Vincent T. H. B. M. Smit, Elma Meershoek-Klein Kranenbarg, Joan B. Heijns, Laurence J. C. van Warmerdam, Lonneke W. Kessels, M. Wouter Dercksen, Manon J. A. E. Pepels, Hanneke W. M. van Laarhoven, Birgit E. P. J. Vriens, Hein Putter, Marta Fiocco, Gerrit-Jan Liefers, Jacobus J. M. van der Hoeven, Johan W. R. Nortier, Judith R. Kroep, on behalf of the Dutch Breast Cancer Research Group
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Breast Cancer Research
Subjects:
Breast cancer
Neoadjuvant chemotherapy
Zoledronic acid
Survival
Insulin
IGF-1R
Online Access:http://link.springer.com/article/10.1186/s13058-019-1180-6

Internet

http://link.springer.com/article/10.1186/s13058-019-1180-6

Similar Items